

**10th January 2020**

**Nuformix plc**  
("Nuformix" or "the Group"),

**Issue of Equity**

Nuformix, the pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs announces that following the receipt of Notice of Exercise, 1,250,000 ordinary shares of 0.1p each in the Group (the "Warrant Shares") have now been issued to the warrant holder following exercise at the agreed price of 4p per share.

Application has been made to admit the Warrant Shares to trading on the London Stock Exchange on 10 January 2020, and dealings in the Warrant Shares are expected to commence on 14 January 2020

Following the issue of the Warrant Shares the total number of shares now in issue is 490,145,083 ordinary shares with voting rights attached (one vote per share). There are no shares held in treasury.

This total voting rights figure may be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify their interests in, or a change to their interest in, Nuformix plc under the Disclosure and Transparency Rules.

*Market Abuse Regulation (MAR) Disclosure. Certain information contained in this announcement would have been deemed inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 until the publication of this announcement via a Regulatory Information Service and accordingly, this inside information is now considered to be in the public domain.*

**Enquiries:**

**Nuformix plc**  
**Dr Dan Gooding, Chief Executive Officer**  
**Email: [info@nuformix.com](mailto:info@nuformix.com)**

+44 (0)1223 627222

**Novum Securities Limited**  
**Jon Belliss / Colin Rowbury**

+44 (0)20 7399 9427

**About Nuformix plc [www.nuformix.com](http://www.nuformix.com)**

Nuformix is a pharmaceutical development company using cocrystal

technology to unlock the therapeutic potential of approved small molecule drugs. Nuformix's risk-mitigated development strategy has resulted in a pipeline of discoveries through which it has developed and patented novel cocrystal forms of approved small molecules.

Nuformix has created an IP portfolio of granted patents covering cocrystal forms of five small molecule drugs. Nuformix is targeting high-value unmet needs with its lead programmes in oncology supportive care: NXP001 and fibrosis: NXP002.

Nuformix was established in Cambridge in 2009 and has invested in pharmaceutical cocrystal R&D, establishing world-class capability and know-how in cocrystal discovery and development, yielding multiple product opportunities.

Nuformix plc shares are traded on the London Stock Exchange's Official List under the ticker: NFX.L.

### **About Fibrosis**

Fibrotic disease is typically associated with high patient mortality, increasing prevalence and a lack of safe and effective treatments. Whilst, fibrosis treatments are in their infancy the emerging lung fibrosis market demonstrates their blockbuster potential. Markets for other fibrotic conditions are under-developed, with large and growing patient populations (e.g. the global liver disease market is predicted to reach \$12.1 billion by 2022). IPF is classified as a rare disease and presents a global commercial market that is forecast to grow to \$5bn by 2025.